Ipsen — Capital/Financing Update 2023

Jul 10, 2023

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

Paris (France), July 10, 2023 - Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2023, the following resources were included to the dedicated liquidity account:

• 17,348 shares
• €3,350,842.85

It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:

• 12,751 shares
• €3,137,934.80

Between January 1 st, 2023 and June 30, 2023 have been executed:

• 3,153 purchase transactions
• 2,820 sell transactions

Under the same period, the volumes traded represented:

• 360,894 shares and €38,313,096.35 to the purchase
• 367,615 shares and €39,180,843.15 to the sell

Ipsen

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company's research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and lifescience hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,000 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Contacts

Investors

Craig Marks

Vice President, Investor Relations

+44 7584 349 193

Media

Amy Wolf

Vice President and Head of Corporate Brand Strategy and Communications +41 79 576 07 23

Nicolas Bogler Senior Manager, Investor Relations +33 (0) 6 52 19 98 92

Ioana Piscociu

Senior Manager, Global Media Relations

+33 6 69 09 12 96